1216 related articles for article (PubMed ID: 33707409)
21. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
22. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
23. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
24. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
25. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
26. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
[TBL] [Abstract][Full Text] [Related]
27. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
[TBL] [Abstract][Full Text] [Related]
28. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
[TBL] [Abstract][Full Text] [Related]
29. Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
Augustine J; Hricik DE
Adv Chronic Kidney Dis; 2016 Sep; 23(5):301-305. PubMed ID: 27742384
[TBL] [Abstract][Full Text] [Related]
30. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
31. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
32. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
33. mTOR Inhibition and Clinical Transplantation: Heart.
Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Johnson SC; Martinez F; Bitto A; Gonzalez B; Tazaerslan C; Cohen C; Delaval L; Timsit J; Knebelmann B; Terzi F; Mahal T; Zhu Y; Morgan PG; Sedensky MM; Kaeberlein M; Legendre C; Suh Y; Canaud G
Kidney Int; 2019 Feb; 95(2):455-466. PubMed ID: 30471880
[TBL] [Abstract][Full Text] [Related]
36. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
37. Impact of immunosuppression regimen on COVID-19 mortality in kidney transplant recipients: Analysis from a Colombian transplantation centers registry.
Montero C; Torres R; Benavidez C; Garcia P; Jimenez S; Yomayusa N; Gayon D; Perez J; Rosselli D; Restrepo H; Alvarez-Moreno C
Nefrologia (Engl Ed); 2023; 43(6):757-764. PubMed ID: 36681519
[TBL] [Abstract][Full Text] [Related]
38. Medical Aspects of mTOR Inhibition in Kidney Transplantation.
Cuadrado-Payán E; Diekmann F; Cucchiari D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887051
[TBL] [Abstract][Full Text] [Related]
39. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation.
Korucu B; Yeter H; Guz G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Apr; 43(1):101-107. PubMed ID: 35451298
[No Abstract] [Full Text] [Related]
40. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]